Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSAS-1842856 is a potent inhibitor of forkhead box class O transcription factor 1 (FoxO1; IC50 = 33 nM in HepG2 cells).1 Inhibition of FoxO1-mediated transactivation with AS-1842856 leads to a dose-dependent decrease in expression of glucose-6 phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) mRNA and inhibits glucogenesis in rat hepatoma Fao cells and a murine model of type 2 diabetes mellitus (T2DM). AS-1842856 also inhibits 3T3-L1 preadipocyte differentiation and reduces lipid droplet growth in adipocytes.2,3
WARNING This product is not for human or veterinary use.
1. Discovery of novel forkhead box O1 inhibitors for treating Type 2 Diabetes: Improvement of fasting glycemia in diabetic db/db mice. Mol. Pharmacol. 78(5), 961-970 (2010).
2. FoxO1 antagonist suppresses autophagy and lipid droplet growth in adipocytes. Cell Cycle 15(15), 2033-2041 (2016).
3. Targeting FoxO1 with AS1842856 suppresses adipogenesis. Cell Cycle 13(23), 3759-3767 (2014).